The PD-L1 Inhibitors drugs uptake section examines the rate at which newly launched or upcoming potential drugs are being ...

Pfizer PFE is one of the largest and most successful drugmakers in oncology. It boasts a strong portfolio of approved cancer ...

The big question thrown up in the results, however, is the role of Imfinzi, given that PD-1/PD-L1 checkpoint inhibitors have until now largely failed to move the needle in advanced ovarian cancer ...

Imfinzi is already approved for unresectable ... but in tumours that express PD-L1 in 1% of cells or more. MSD, meanwhile, also has a green light for Keytruda as perioperative therapy for patients ...

With a backdrop of mounting industry disruption and transition, Pharm Exec’s latest listing of the top global biopharma sales ...

Durvalumab (Imfinzi) is a PD-L1–blocking antibody that has 3 indications for non–small cell lung cancer (NSCLC). February ...

The American Journal of Managed Care provides insights into the latest news and research in managed care across multimedia ...

During a live event, Neal E. Ready, MD, and participants discussed use of PD-L1 status in non–small cell lung cancer and ...

Researchers have uncovered another piece of the Parkinson’s disease puzzle, identifying that particular immune cells are ...

Roche's Venclexta failure does not affect the oncology pipeline, as HER2 franchise continues to drive revenue growth. Click ...